Skip to Content
MilliporeSigma
Get 22% off for Pi Day through March 31.Save Now

SML2487

Cabazitaxel

≥95% (HPLC), taxane microtubule inhibitor, powder

Synonym(s):

1-hydroxy-7β,10β-dimethoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-[[(tert-butoxy)carbonyl]amino]-2-hydroxy-3-phenylpropanoate], DEP cabazitaxel, Jevtana, TXD 258, XRP 6258, XRP-6258, dimethoxydocetaxel

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

5 MG

$97.90

25 MG

$395.00

$97.90

Check Cart for Availability
​
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C45H57NO14
CAS Number:
183133-96-2
Molecular Weight:
835.93
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD18827611
Assay:
≥95% (HPLC)
Form:
powder

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Cabazitaxel, ≥95% (HPLC)

assay

≥95% (HPLC)

form

powder

optical activity

[α]/D -36 to -44°, c = 0.5 in methanol

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

N([C@H]([C@@H](O)C(=O)O[C@H]2C[C@]3([C@H]([C@@H]5[C@]6([C@H](OC6)C[C@@H]([C@]5(C(=O)[C@@H](C(=C2C)C3(C)C)OC)C)OC)OC(=O)C)OC(=O)c4ccccc4)O)c1ccccc1)C(=O)OC(C)(C)C

InChI

1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1

InChI key

BMQGVNUXMIRLCK-OAGWZNDDSA-N

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
SML2352SML0147SML3135
Cabazitaxel ≥95% (HPLC)

Sigma-Aldrich

SML2487

Cabazitaxel

Aramchol ≥98% (HPLC)

Sigma-Aldrich

SML2352

Aramchol

Drospirenone ≥98% (HPLC)

Sigma-Aldrich

SML0147

Drospirenone

Cinobufagin ≥98% (HPLC)

Sigma-Aldrich

SML3135

Cinobufagin

assay

≥95% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

−20°C

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: ≥15

solubility

DMSO: 2 mg/mL, clear

color

white to beige

color

white to beige

color

white to tan

color

white to beige

optical activity

[α]/D -36 to -44°, c = 0.5 in methanol

optical activity

-

optical activity

[α]/D -180 to -195°, c = 1 in methanol

optical activity

-

Biochem/physiol Actions

Cabazitaxel is a synthetic taxane microtubule inhibitor and anticancer agent. It acts by stabilization of microtubules, promoting tubulin assembly into microtubules but inhibiting disassembly, resulting in the inhibition of mitotic and interphase cellular functions.
Synthetic taxane microtubule inhibitor

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Muta. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 2

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000334126
0000334126
0000279142
0000279142
0000279143

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sheel A Patel et al.
OncoTargets and therapy, 10, 4089-4098 (2017-09-02)
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are now multiple effective and approved agents for
Takeo Kosaka et al.
Cancer chemotherapy and pharmacology, 82(6), 1061-1066 (2018-10-05)
The correlation of the oncological outcomes of docetaxel and cabazitaxel in Japanese metastatic castration-resistant prostate cancer (mCRPC) patients has not been unclear. This study included a total of 47 consecutive Japanese mCRPC patients treated with cabazitaxel and assessed the prognostic
Patricia Vrignaud et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 19(11), 2973-2983 (2013-04-17)
Taxanes are important chemotherapeutic agents with proven efficacy in human cancers, but their use is limited by resistance development. We report here the preclinical characteristics of cabazitaxel (XRP6258), a semisynthetic taxane developed to overcome taxane resistance. Cabazitaxel effects on purified
Maria J Martinez et al.
iScience, 26(9), 107681-107681 (2023-09-14)
Men with incurable castration resistant prostate cancer (CRPC) are typically treated with taxanes; however, drug resistance rapidly develops. We previously identified a clinically relevant seven gene network in aggressive CRPC, which includes the spindle assembly checkpoint (SAC) kinase BUB1. Since
Buse Cevatemre et al.
Cell death & disease, 15(2), 132-132 (2024-02-13)
The development of taxane resistance remains a major challenge for castration resistant prostate cancer (CR-PCa), despite the effectiveness of taxanes in prolonging patient survival. To uncover novel targets, we performed an epigenetic drug screen on taxane (docetaxel and cabazitaxel) resistant

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service